Adeia Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Adeia Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $443.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $376.02M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $388.79M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $438.93M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $391.21M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $515.92M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $280.07M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $406.13M | Feb 26, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $443.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $376.02M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $388.79M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $103.29M | Feb 19, 2025 |
| FY2024 | Sep 30, 2022 | $89.30M | Feb 19, 2025 |
| FY2024 | Jun 30, 2022 | $107.82M | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | $138.53M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $89.71M | Feb 23, 2024 |
| FY2023 | Sep 30, 2021 | $101.65M | Feb 23, 2024 |
| FY2023 | Jun 30, 2021 | $101.85M | Feb 23, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $64.62M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $67.37M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $73.73M | Feb 19, 2025 |
| FY2024 | Sep 30, 2022 | ($388.93M) | Feb 19, 2025 |
| FY2024 | Jun 30, 2022 | ($5.63M) | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | $24.94M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($14.56M) | Feb 23, 2024 |
| FY2023 | Sep 30, 2021 | ($45.07M) | Feb 23, 2024 |
| FY2023 | Jun 30, 2021 | ($1.12M) | Feb 23, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $175.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $128.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $136.23M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $33.24M | Feb 19, 2025 |
| FY2024 | Sep 30, 2022 | $15.64M | Feb 19, 2025 |
| FY2024 | Jun 30, 2022 | $34.72M | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | $69.45M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $16.97M | Feb 23, 2024 |
| FY2023 | Sep 30, 2021 | $37.49M | Feb 23, 2024 |
| FY2023 | Jun 30, 2021 | $31.46M | Feb 23, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $59.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $54.26M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $44.58M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $39.61M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $35.08M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $110.85M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $104.86M | Feb 26, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.53M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $103.44M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $95.23M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $135.63M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $129.21M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $136.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $117.67M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $122.78M | Feb 26, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $212.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $152.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $183.02M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $234.79M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $427.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $169.25M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $135.13M | Feb 26, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.82M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.81M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $12.58M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $13.95M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $7.38M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $8.81M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.34M | Feb 26, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.11B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.21B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.47B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.70B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.05B | Feb 26, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $558.76M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $701.39M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $748.93M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $909.11M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.25B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $502.85M | Feb 26, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.54M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $396.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $356.62M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $301.41M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.46B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $547.91M | Feb 26, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $313.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $313.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $313.66M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $313.66M | Feb 23, 2024 |
| FY2023 | Dec 31, 2021 | $314.58M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $314.58M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $385.78M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $385.78M | Feb 26, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.83M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($56.33M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($123.70M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $187.81M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $264.25M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $148.32M | Feb 26, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $78.83M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $54.56M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $114.56M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $80.43M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $170.19M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $74.55M | Feb 26, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.45M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $475.46M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $585.70M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $729.39M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $765.49M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $839.35M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $334.68M | Feb 26, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2024 | Sep 30, 2022 | (3) | Feb 19, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2023 | Sep 30, 2021 | 0 | Feb 23, 2024 |
| FY2023 | Jun 30, 2021 | 0 | Feb 23, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 19, 2025 |
| FY2024 | Sep 30, 2022 | (3) | Feb 19, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2022 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 23, 2024 |
| FY2023 | Sep 30, 2021 | 0 | Feb 23, 2024 |
| FY2023 | Jun 30, 2021 | 0 | Feb 23, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 109.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 108.07M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 107.38M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 105.17M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 103.26M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 104.78M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 49.62M | Feb 26, 2021 |